The stock price for Haemonetics Corp (HAE) currently stands at $57.39. The stock experienced a substantial increase in the last session, hitting $108.0 after starting at $58.63. The stock’s lowest price was $68.0 before closing at $75.77.
The market performance of Haemonetics Corp’s stock has been turbulent in recent times.
52-week price history of HAE Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Haemonetics Corp’s current trading price is -39.58% away from its 52-week high, while its distance from the 52-week low is 3.78%. The stock’s price range during the 52-week period has remained between $55.30 and $94.99. In the Healthcare sector, the company’s shares saw a trading volume of around 2.17 million for the day, which was evidently higher than the average daily volume of 0.57 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Haemonetics Corp (HAE) has experienced a quarterly decline of -10.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.76B and boasts a workforce of 3023 employees.
A Closer Look at Analysts’ Ratings for Haemonetics Corp
As of right now, 5 analysts are rating Haemonetics Corp as a BUY, 5 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 68.27, with a change in price of -7.77. Similarly, Haemonetics Corp recorded 622,732 in trading volume during the last 100 days, posting a change of -11.87%.
Examining HAE’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for HAE stands at 1.56. Similarly, the long-term debt-to-equity ratio is also 1.18.
HAE Stock Stochastic Average
Haemonetics Corp’s raw stochastic average for the past 50 days is presently 4.70%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 5.18%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 35.17% and 44.39%, respectively.
HAE Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -33.73%. However, over the past six months, we’ve seen a stronger performance of -19.44%. The price of HAE leaped by -25.97% over the last 30 days. And in the last five days, it has fallen by -22.49%.
